Novartis's Kymriah wins speedy reviews in U.S., Europe

ZURICH (Reuters) - Novartis has been granted fast-track reviews of its cell therapy Kymriah for blood cancers in the United States and Europe, the Swiss drugmaker said on Wednesday, as it seeks to expand the pool of patients eligible for the costly treatment.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news